Natural Remedies for Perimenopause Symptoms: 2026 Clinical Update

Clinical note: This article is for informational purposes and does not constitute medical advice. Natural remedies described here are adjunctive and should not replace individualized care from a licensed clinician. Women with hormone-sensitive conditions, hepatic disease, or those taking prescription medications should consult their provider before using any botanical supplement. Hormone therapy (HT) remains the most effective first-line treatment for moderate-to-severe vasomotor symptoms per NAMS and The Menopause Society.

Understanding Perimenopause

Perimenopause refers to the transitional phase preceding the final menstrual period, typically beginning in the mid-to-late 40s and lasting two to eight years. It is defined by erratic fluctuations and eventual decline in ovarian estrogen and progesterone production — changes that drive a wide spectrum of physiological and psychological symptoms.

Common symptom clusters include vasomotor symptoms (VMS) — hot flashes and night sweats — which affect an estimated 36–50% of perimenopausal women in North America.¹ Additional concerns span disrupted sleep, mood instability, reduced libido, cognitive changes, genitourinary discomfort, and accelerating bone loss.

While menopausal hormone therapy (MHT) remains the most clinically effective intervention for VMS and genitourinary syndrome of menopause (GSM),² a substantial proportion of women either cannot use hormones (due to contraindications including hormone-sensitive cancers or prior thromboembolic events) or prefer to explore non-hormonal options first. Notably, the FDA initiated removal of the longstanding “black box” warning on MHT labeling in November 2025, citing updated evidence supporting safety within the 10-year post-menopause window and before age 60.³

This article synthesizes the current state of evidence for natural and lifestyle-based interventions, graded using the framework adopted by The Menopause Society (NAMS).

How Evidence Is Graded in This Article

The NAMS 2023 Nonhormone Therapy Position Statement evaluated interventions using a three-tier evidence hierarchy:⁴

Level I — Recommended

• Good, consistent scientific evidence
• Multiple high-quality RCTs
• Used as the benchmark in this review

Level II — Limited evidence

• Limited or inconsistent RCT data
• Promising but not conclusive
• May still be appropriate in practice

Level III — Expert opinion

• Consensus or expert opinion only
• Minimal controlled trial data
• Generally not recommended by NAMS

Where NAMS has not evaluated a specific intervention, the most current peer-reviewed systematic review or meta-analysis is cited and labeled accordingly.

Mind-Body Interventions

Mind-body therapies represent the most robustly supported category of non-hormonal natural interventions. NAMS assigns Level I evidence — its highest rating — to two approaches within this category.

Cognitive Behavioral Therapy (CBT)

NAMS Level I

CBT is the most thoroughly validated non-pharmacological intervention for perimenopausal VMS, insomnia, depression, and anxiety. A 2025 systematic review covering 16 studies (910 women, publications 1990–2024) found that CBT in group, individual, and self-help formats significantly reduced hot flash frequency and severity, improved sleep quality, and reduced anxiety and depression scores compared with control conditions.⁵

For perimenopause-associated insomnia specifically, CBT for Insomnia (CBT-I) has demonstrated superiority over sleep hygiene education alone. A landmark MsFLASH trial delivered CBT-I via telephone to perimenopausal and postmenopausal women with co-occurring VMS and insomnia, yielding clinically meaningful improvements in sleep onset latency and wakefulness after sleep onset.⁶

Key mechanisms

• Restructures catastrophic appraisals of hot flash episodes, reducing their perceived interference
• Teaches paced breathing, relaxation, and stimulus control to interrupt the hot flash–arousal cycle
• Addresses maladaptive sleep beliefs that perpetuate insomnia independent of VMS burden

Access options

• In-person individual or group therapy with a licensed cognitive behavioral therapist
• Validated self-help workbooks (e.g., the MENOS series developed by Prof. Myra Hunter, King’s College London)
• Digital CBT-I platforms (several are currently FDA-cleared for chronic insomnia)

Clinical Hypnosis

NAMS Level I

Clinical hypnosis — distinct from stage hypnosis — involves therapist-guided relaxation and targeted suggestion to alter the perception and physiological response to VMS. NAMS rates it Level I based on a program of rigorous RCTs.⁴ The most pivotal trial, the Hypnotic Relaxation Therapy (HRT) study led by Gary Elkins, PhD (Baylor University), found a 74% reduction in weekly hot flash scores in postmenopausal women versus control. Importantly, the intervention improved sleep and quality of life concurrently.

Clinical considerations

• Requires a licensed clinical hypnotherapist with training in menopause symptom management
• Typically delivered in 5 weekly sessions; audio recordings extend benefit between appointments
• No known drug interactions; appropriate for women with MHT contraindications

Mindfulness-Based Interventions

NAMS Level II

Mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT) have demonstrated consistent benefit for perimenopausal mood disturbance, anxiety, and quality of life, though direct evidence for VMS reduction remains limited and inconsistent. NAMS assigns Level II: the interventions are not explicitly recommended for hot flash reduction but may be offered for the broader psychological symptom burden of perimenopause.⁴

Paced respiration (slow, deep breathing during a hot flash) was specifically evaluated by NAMS and found not to significantly reduce VMS frequency when studied rigorously (Level I evidence of no benefit).

“CBT and clinical hypnosis now have the kind of RCT evidence base we would expect of any pharmacological agent. Clinicians should be routinely offering these as first-line options alongside MHT discussions, not as an afterthought.”

— Aligned with position of NAMS 2023 Nonhormone Therapy Advisory Panel, led by Chrisandra L. Shufelt, MD, MS, FACP, NCMP

Exercise & Physical Activity

Regular physical activity is among the most clinically important lifestyle interventions available during perimenopause, with evidence spanning bone health, cardiovascular risk, mood, sleep, and quality of life — even where direct VMS reduction is less certain.

Aerobic Exercise

NAMS Level II

A 2025 systematic review and meta-analysis (8 RCTs, publications 2014–2024) confirmed that regular aerobic exercise significantly improves overall menopausal symptom scores and quality of life, with particularly consistent effects on insomnia, irritability, fatigue, and joint pain.⁷ Direct reduction in hot flash frequency showed inconsistent results across trials — NAMS accordingly classifies aerobic exercise as Level II for VMS specifically.

Studied modalities with evidence include brisk walking, jogging, swimming, cycling, and aerobics. Most trials achieving significant outcomes used at least 30 minutes of moderate-intensity activity, at least three days per week, sustained over six to twelve weeks.

Sleep benefit

Six months of moderate aerobic activity produced significant improvements in sleep quality in perimenopausal women in multiple RCTs,⁷ making it a valuable adjunct to CBT-I for women with sleep-onset or sleep-maintenance insomnia.

Resistance Training

NAMS Level II

Resistance training carries particular importance during the menopausal transition given accelerating bone mineral density (BMD) loss. A 2025 scoping review found that resistance exercise during perimenopause and early postmenopause slowed BMD loss and in several programs increased pelvic BMD relative to controls.⁸ Additional trial-level evidence suggests resistance training may modulate luteinizing hormone (LH) levels — a plausible mechanism by which it could reduce VMS burden over time.

• FLAMENCO project (16-week resistance protocol): significant improvements in self-perceived health, vaginal dryness, mental well-being, and BMD compared with controls
• Recommended frequency: 2–3 sessions per week targeting major muscle groups
• Evidence strongest when initiated during perimenopause rather than late postmenopause

Clinical bottom line: Exercise is not yet evidence-based for directly reducing hot flash frequency (Level II — inconsistent trials), but its comprehensive benefits for bone density, mood, sleep, metabolic risk, and quality of life make it a clinical priority during perimenopause, with a strong safety profile. The 2025 frontiers of endocrinology meta-analysis supports 2–4 sessions/week for bone metabolism benefit in perimenopausal women.⁸

Diet & Nutrition

Nutritional strategies during perimenopause are most strongly supported for bone health, cardiovascular risk modification, and metabolic stabilization. Dietary approaches aimed directly at hot flash reduction carry more limited and mixed evidence.

Soy isoflavones and phytoestrogens

Soy foods and soy isoflavone extracts are the most extensively studied dietary interventions for VMS. Isoflavones (genistein, daidzein) bind weakly to estrogen receptors and may modulate thermoregulatory pathways. NAMS (2023) classifies both soy foods and soy extracts as Level II — not specifically recommended for VMS — citing evidence inconsistency across trials.⁴

A 2021 overview published in Nutrients (PMC8004126) noted that while some women — particularly equol producers, roughly 30–50% of Western women — may experience meaningful hot flash reduction from isoflavone supplementation, population-level effects remain modest and inconsistent.⁹ The equol metabolite from soy fermentation is classified separately by NAMS, also at Level II.

Calcium and vitamin D

Bone loss accelerates in the perimenopause due to estrogen withdrawal. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) recommends that women aged 51 and older consume 1,200 mg of calcium daily (through food first, supplemented as needed) and maintain adequate vitamin D to support calcium absorption.¹⁰ Weight-bearing exercise compounds this benefit. These are foundational, not optional, during the menopausal transition.

Anti-inflammatory dietary patterns

Mediterranean-style diets — characterized by high intake of vegetables, legumes, whole grains, olive oil, and fatty fish — are associated with lower cardiovascular risk in midlife women and may attenuate the degree of menopausal symptom burden through anti-inflammatory mechanisms, though direct RCT evidence specific to VMS remains sparse (Level III).

Practical dietary targets during perimenopause

• Calcium: 1,200 mg/day (women 51+) — prioritize dairy, fortified plant milks, canned salmon, leafy greens
• Vitamin D: 600–800 IU/day; test serum 25(OH)D and supplement to correct deficiency
• Limit alcohol: even moderate intake may lower the threshold for hot flash episodes
• Limit caffeine: particularly in the afternoon and evening, given sleep disruption risk
• Spicy food triggers: individual — keep a symptom diary to identify personal VMS triggers
• Weight management: emerging evidence (Level II) supports that weight loss reduces VMS frequency in overweight perimenopausal women⁴

Botanical Supplements: What the Evidence Actually Shows

Botanical supplements are widely purchased by perimenopausal women, yet the majority lack rigorous evidence of efficacy. NAMS has explicitly evaluated the most common ones. This section provides an honest appraisal, including supplements the evidence does not support.

Safety note: Botanical supplements are not regulated as pharmaceuticals in the United States. Purity, potency, and safety profiles vary significantly between brands. Women with hormone-sensitive conditions (breast cancer, uterine cancer), hepatic disease, or who take anticoagulants, SSRIs, or other medications should consult their provider before use.

Black Cohosh (Actaea racemosa)

NAMS: Insufficient Evidence

Black cohosh is the single most purchased botanical for menopause symptoms in the United States. Despite its widespread use, the NAMS 2023 position statement concludes there is insufficient evidence to support its use for VMS at this time (Level I — multiple high-quality trials show no benefit over placebo).⁴ Its mechanism of action remains unclear; earlier assumptions of estrogenic activity have not been consistently confirmed.

Additionally, rare but documented cases of hepatotoxicity have been associated with black cohosh use. Women with liver disease or elevated transaminases should avoid it.

Soy Isoflavone Supplements

NAMS Level II

Supplemental isoflavones are classified Level II (limited/inconsistent evidence) — distinct from whole soy foods in the evidence literature. Women who are equol producers may respond better to isoflavone supplementation, though commercial equol-producer tests are not yet widely available. Women with a history of estrogen receptor-positive breast cancer should discuss phytoestrogen use with their oncologist.

Pycnogenol (Pine Bark Extract)

NAMS Level II / Emerging

A 2024 review of double-blind, placebo-controlled RCTs found that Pycnogenol (standardized French maritime pine bark extract) may improve hot flashes and other perimenopausal symptoms in some trials.¹¹ Evidence remains mixed — some included trials showed no effect — and NAMS has not yet formally classified this supplement in its 2023 statement. It represents an area of active research interest rather than established practice.

Supplements with insufficient or negative evidence

NAMS does not recommend the following for VMS based on Level I or Level II evidence reviews: dong quai, wild yam extract, evening primrose oil, maca, red clover, vitamin E (in VMS-specific doses), and Vitex agnus-castus (chaste tree berry). This does not preclude their use for other indications, but women should not rely on them for hot flash management.

Cannabinoids (CBD, THC) are rated Level II — not recommended for VMS — with insufficient controlled data, though research is ongoing.⁴

Sleep Hygiene Strategies

Sleep disturbance in perimenopause is multifactorial: nocturnal vasomotor symptoms disrupt sleep architecture, while concurrent anxiety, mood changes, and primary sleep disorders (such as obstructive sleep apnea, which increases post-menopause) compound the problem.

Evidence-supported sleep hygiene practices

While sleep hygiene education (SHE) alone is classified Level III (insufficient for standalone use), the following practices form an evidence-informed foundation to support CBT-I or pharmacological treatment:

• Maintain a consistent sleep and wake schedule, including weekends — anchors circadian rhythm
• Keep the bedroom cool (60–67°F / 15–19°C) — reduces thermoregulatory trigger thresholds for hot flashes
• Use moisture-wicking, layered bedding to manage night sweats without overcooling
• Limit screen exposure in the 60 minutes before bed — blue light suppresses melatonin secretion
• Avoid alcohol within 3 hours of bedtime — disrupts REM architecture and can provoke vasomotor episodes
• Reserve the bed for sleep and sex only (stimulus control — core component of CBT-I)
• If unable to sleep after 20 minutes, get up and engage in quiet, non-stimulating activity until sleepy

For perimenopausal women whose sleep disturbance is primarily driven by nocturnal VMS rather than primary insomnia, adequately treating the VMS (via MHT or CBT) typically produces concurrent sleep improvement. CBT-I delivered by telephone has demonstrated efficacy specifically in this population per the published MsFLASH trial.⁶

Quick Reference: Evidence Summary Table

This table summarizes the primary target symptoms and NAMS evidence classification for each intervention covered in this article.

Intervention	Primary target symptom(s)	NAMS / evidence level	Notable caveat
CBT / CBT-I	Hot flashes, insomnia, anxiety, depression	Level I — recommended	Access and cost vary; digital options expanding
Clinical hypnosis	Hot flashes, sleep, quality of life	Level I — recommended	Requires trained clinician; not widely available
Aerobic exercise	Sleep, mood, overall QoL, cardiovascular risk	Level II	Direct VMS reduction inconsistent across trials
Resistance training	Bone density, muscle mass, mood	Level II	Critical for osteoporosis prevention — start early
Weight loss	Hot flash frequency (in overweight women)	Level II–III	Effect size modest; lifestyle intervention required
Soy isoflavones (food)	Hot flashes (equol producers)	Level II	Inconsistent; caution in ER+ breast cancer history
Calcium + vitamin D	Bone density (fracture prevention)	Strongly supported (NIAMS)	Food-first; supplement to correct deficiency
Black cohosh	Hot flashes (intended)	Level I — NOT recommended	No benefit over placebo; hepatotoxicity risk
Mindfulness (MBSR/MBCT)	Anxiety, mood, perceived QoL	Level II	Limited direct VMS evidence; strong psychological data
Pycnogenol	Hot flashes, general VMS	Emerging (mixed RCTs)	Not yet formally classified by NAMS 2023
Dong quai, wild yam, EPO	Hot flashes (intended)	NOT recommended	No consistent clinical evidence of benefit

When to Discuss Options with Your Clinician

Natural remedies are most appropriate as adjuncts to, not replacements for, comprehensive clinical management. Seek evaluation from a clinician with menopause expertise — ideally one certified by The Menopause Society (NCMP credential) — if you experience any of the following:

• Seven or more hot flashes per day, or night sweats that regularly disrupt sleep
• New or worsening depressive symptoms during the menopausal transition
• Genitourinary symptoms (vaginal dryness, dyspareunia, urinary urgency) affecting quality of life
• Bone density loss identified on DXA scan
• Premature ovarian insufficiency (POI) — cessation of periods before age 40
• Symptoms that have not responded after 8–12 weeks of consistent lifestyle intervention

Finding a certified clinician: The Menopause Society maintains a searchable Menopause Practitioner locator for board-certified practitioners (NCMP) in the United States. The North American Menopause Society was renamed The Menopause Society in 2023.

References & Sources

1. Philip A, et al. (2025). Exercise and perimenopausal syndrome: A systematic review of RCTs. Cureus, 17(3): e80862. Full text (Cureus)
2. The Menopause Society (formerly NAMS). (2022). The 2022 Hormone Therapy Position Statement. Menopause, 29(7). PubMed abstract
3. ObG Project. (2025–2026). The Menopause Society: Hormone Therapy Statement — FDA black box removal update (November 2025). ObG Project summary
4. Shufelt CL, et al. (2023). The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause, 30(6):573–590. LWW full statement | PubMed
5. Al-Safi ZA, et al. (2025). Cognitive Behavioural Therapy for menopausal symptoms: A systematic review of efficacy in improving quality of life. PMC. Full text (PMC)
6. McCurry SM, et al. (2016). Telephone-based CBT for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms: A MsFLASH randomized clinical trial. JAMA Internal Medicine, 176(7):913–920. PubMed
7. Avilés-Martínez MA, et al. (2025). Effects of physical exercise on symptoms and quality of life in women in climacteric: A systematic review and meta-analysis. Healthcare, 13(6):644. Full text (MDPI)
8. Platt L, et al. (2025). Impact of menopause hormone therapy, exercise, and their combination on bone health: A scoping review. Frontiers in Reproductive Health. Full text (Frontiers)
9. Chen L-R, et al. (2021). Utilization of isoflavones in soybeans for women with menopausal syndrome: An overview. Nutrients. PMC full text
10. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). (2023). Calcium and Vitamin D: Important for Bone Health. NIAMS.nih.gov
11. Weichmann F, et al. (2024). Pycnogenol French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies. PMC. PMC full text
12. Kim J-H, Yu H-J. (2024). The effectiveness of cognitive behavioral therapy on depression and sleep problems for climacteric women: A systematic review and meta-analysis. Journal of Clinical Medicine, 13(2):412. PMC full text
13. Lozza-Fiacco S, et al. (2024). The effectiveness of CBT on insomnia severity among menopausal women: A scoping review. PMC. PMC full text
14. Kim DS, et al. (2024). Efficacy of cognitive behavioral therapy for menopausal symptoms and quality of life in Korean perimenopausal women: A pilot RCT. Maturitas, 189:108103. PubMed
15. Zhang Y, et al. (2025). Effects of exercise on bone metabolism in postmenopausal women: Meta-analysis of RCTs. Frontiers in Endocrinology. Full text (Frontiers)
16. Kapoor E, et al. (2023–2025). Menopausal hormone therapy: Risks, benefits and emerging options. Narrative review. PMC. PMC full text

Disclosure: This article was prepared for informational and educational purposes. No commercial relationships or financial conflicts of interest influenced the content. No products are promoted or sold. All outbound links connect to peer-reviewed publications, government health resources, or major professional society websites. This post follows our Editorial Process to ensure scientific accuracy and transparency.

Last updated: April 2026  |  Review cycle: Annually or upon major guideline update  |  Evidence standard: The Menopause Society / NAMS 2023 Nonhormone Therapy Position Statement and subsequent peer-reviewed literature through early 2026.